Here are four things to know.
1. The FDA approved Bavencio to treat advanced or metastatic bladder cancer in patients whose disease still progresses after chemotherapy.
2. New York City-based Pfizer developed the drug with Darmstadt, Germany-based Merck. As part of the accelerated approval, the drugmakers must conduct another clinical trial to confirm the drug’s efficacy for this treatment indication.
3. The drug will cost about $13,000 a month for the average bladder cancer patient, according to German Merck.
4. The decision comes just two months after Bavencio received FDA approval to treat a rare form of skin cancer.
More articles on supply chain:
WHO calls for global drug price transparency
Patients barter for costly medications on Facebook
PhRMA issues new membership criteria, boots more than 20 drugmakers
